Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…Abstract Number: 2392 • 2017 ACR/ARHP Annual Meeting
Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
ABSTRACT Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A systematic review and meta-analysis Background/Purpose: Interstitial lung disease affects 10-15%…Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…Abstract Number: 2402 • 2017 ACR/ARHP Annual Meeting
Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients
Background/Purpose: Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD).…Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting
Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…Abstract Number: 2412 • 2017 ACR/ARHP Annual Meeting
Mortality and Clinical Features in Rheumatoid Arthritis and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the most common extra-articular manifestation in Rheumatoid Arthritis (RA) generating higher mortality in these patients. The objective is to…Abstract Number: 1559 • 2016 ACR/ARHP Annual Meeting
Shared Genetic Predisposition in Rheumatoid Arthritis–Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Genetic Association Study
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality for rheumatoid arthritis (RA) patients. Despite its high prevalence and mortality, little…Abstract Number: 30 • 2016 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis
Background/Purpose: Some studies have supported ethnicity-related differences in the prevalence of ILD and ILD in RA; however, these results have not yet been conclusive.…Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…Abstract Number: 1884 • 2016 ACR/ARHP Annual Meeting
Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD.…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 18
- Next Page »